To the best of our knowledge, this study for the first time provided reliable causal evidence for the adverse impact of sarcopenia on major cardiometabolic diseases and Alzheimer's disease independent of BF% and physical activity, and elucidated a potential pathway mediated by insulin resistance between sarcopenia and cardiometabolic diseases. The gene discussed is INS; the disease is sarcopenia.